Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Octreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 known ✓ | P30874 | 13/20 | 1.00 |
| ▸ | SSTR5 known ✓ | P35346 | 13/20 | 1.00 |
| ▸ | SSTR4 known ✓ | P31391 | 9/20 | 1.00 |
| ▸ | SSTR3 known ✓ | P32745 | 5/20 | 0.88 |
| ▸ | SSTR1 known ✓ | P30872 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octreotide SCHEMBL15856937 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL18823377 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL17404626 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL17404705 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL17404479 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL18823378 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL23424109 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL21840389 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL21944070 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL17404481 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-3624829-B1 | OCTREOTIDE INJECTION | SUN PHARMACEUTICAL IND LTD (IN) | 2026-01-28 | — | — | EP | claimed |
| EP-3861986-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYPEPTIDES AND RELATED METHODS OF DELIVERY | AMRYT ENDO INC (US) | 2025-11-26 | — | — | EP | claimed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| EP-4448107-B1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | FACULDADE DE FARMACIA DA UNIV DE LISBOA (PT) | 2025-11-05 | — | — | EP | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| US-20250255936-A1 | CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE | ENDO OPERATIONS LIMITED (IE) | 2025-08-14 | — | — | US | claimed |
| EP-3684794-B1 | SOMATOSTATIN PRODRUGS | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIV OF JERUSALEM LTD (IL) | 2025-08-06 | — | — | EP | claimed |
| EP-3212170-B1 | IMPLANTABLE MEDICAL DEVICES FOR EXTENDED RELEASE OF THERAPEUTIC AGENTS | NANO PREC MEDICAL INC (US) | 2025-07-09 | — | — | EP | claimed |
| CN-115181158-B | FMOC group cleavage method | 北京费森尤斯卡比医药有限公司 | 2025-06-13 | — | — | CN | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3288558-B1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma AG (DE) | 2022-05-11 | — | — | EP | claimed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | claimed |
| EP-2087910-B1 | Polymeric prodrugs | ASCENDIS PHARMA GMBH (DE) | 2022-05-04 | — | — | EP | claimed |
| EP-3236937-B1 | CONTROLLED-RELEASE FORMULATIONS | CAMURUS AB (SE) | 2022-05-04 | — | — | EP | claimed |
| US-11318107-B2 | Pharmaceutical active-containing film delivery device for oral transmucosal administration | Avior, Inc. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3976114-A1 | EXTRACELLULAR VESICLES TO DELIVER THERAPEUTIC OR DIAGNOSTIC DRUGS | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2022-04-06 | — | — | EP | claimed |
| EP-3586828-B1 | METHOD FOR PREPARING BIODEGRADABLE MICROSPHERES HAVING IMPROVED STABILITY AND STORAGE STABILITY | G2GBIO INC (KR) | 2022-03-02 | — | — | EP | claimed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | claimed |
| EP-3693375-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES INC (US) | 2022-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255936-A1 | CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE | GHSR, VIPR1, VIPR2 | SSTR2 9/4885SSTR5 13/4885SSTR4 8/4885 |
| US-11318107-B2 | Pharmaceutical active-containing film delivery device for oral transmucosal administration | TAS2R42, TAS2R39, TAS2R45 | SSTR2 1823/4885SSTR5 1757/4885SSTR4 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.